Since mifepristone was approved in 2000, the rate of medical abortions has risen fairly steadily from just 6% of all eligible abortions in 2001 to 29% in 2011. If unconstrained access to medical abortions were the norm, rather than the exception, medical abortions might constitute a higher percentage of all abortions. Furthermore, the on-label use of mifepristone involves use of an outdated regimen of 600 mg that is more expensive and arguably less effective, with greater side effects than the evidence-based regimen of 200 mg that is currently the world-wide standard of care. In order to examine further the possible effect of mifepristone-specific restrictions, researchers documented trends in mifepristone use over a 10-year period (2004–2014) in four large US states: California, New York, Ohio and Texas.

Access full text.

Published:
Nov. 2015
Type:
Staff Publication
Topic:
Medical Abortion, mifepristone
Authors:
Sheldon, Wendy R., Winikoff, Beverly, Sheldon, W., Winikoff, B.

PDF

Not all resources are available in all formats. Select language to check availability.